MiNK Therapeutics Inc.

INKT | NASDAQ

Price Alert Chart Builder DCF Calculator

$12.02

-$0.23 (-1.88%)

Sep 22, 2026, 2:33 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.88%

(1D)

Rating

Updated: Sep 8, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $59.88M

1D Range

11.50 12.38

52W Range

8.48 16.93

Valuation (TTM)

PE -5.13

PB 0.01

EV/EBITDA 1,078.82

Valuation (NTM)

Forward PE N/A

Forward PEG -0.77

Price Target $35

Cash Flow

FCF Yield -3420.6%

SBC Adj. FCF Yield -8492.6%

SBC Impact -148.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 37.0% | 35.2%

FCF 3Y | 5Y -90.3% | -78.7%

Returns

ROA -118.2%

ROE 83.5%

ROIC -604.2%

Financial Health

Net Cash

$8.81B

Current Ratio 1.23

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natur...

Sector Healthcare

Industry Biotechnology

Employees 15

IPO Date Oct 14, 2021

Website minktherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$35

Upside

+191.18%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞